Browse Studies — Arctuva

The MPN PROGRESSion Registry: A Retrospective and Prospective Observational Study Collecting Patient-Reported Outcomes, Electronic Health Records, and Claims Data to Track Symptoms, Treatments, and Disease Progression in Individuals Diagnosed With Myeloproliferative Neoplasms (MPNs).

The MPN PROGRESSion Registry is a multi-year, observational research study designed to improve understanding of myeloproliferative neoplasms (MPNs)-a group of …

Polycythemia VeraET (Essential Thrombocythemia)Polycythemia Vera (PV)+52 more

Estimated

~$10 – $750

MPN Research FoundationNCT07362225

Phase 3

A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

This clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patien…

MyelofibrosisPost-PV MFPost-ET Myelofibrosis+2 more

Estimated

~$10 – $8,750

Kartos Therapeutics, Inc.NCT06479135

Phase 1

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined With Ruxolitinib in Janus-associated Kinase Inhibitor (JAKi) Treatment-Naïve Myelofibrosis (MF) Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis. Partici…

MyelofibrosisPrimary MyelofibrosisPost-PV MF+1 more

Estimated

~$10 – $8,750

Telios Pharma, Inc.NCT05280509